Anticancer agent 50 (compound 6) is a potent ABCB1 efflux pump modulator. Anticancer agent 50 shows cytotoxic effects and antiproliferative effects. Anticancer agent 50 decreases the expression of cyclin D1 and induces p53 expression. Anticancer agent 50 has the potential for the research of T-lymphoma^[1].

Anticancer agent 50 (compound 6) (0-100 µM) shows cytotoxic effects with IC₅₀s of 0.67, 0.90 µM for sensitive parental (PAR) and resistant (MDR) mouse T-lymphoma cells, respectively^[1].
Anticancer agent 50 (0-100 µM) shows antiproliferative effects with IC₅₀s of 3.84, 1.34 µM for sensitive parental (PAR) and resistant (MDR) mouse T-lymphoma cells, respectively^[1].
Anticancer agent 50 (0.1, 0.5, 2 µM; 24 h) inhibits cell cycle progression through the reduction of the expression of cyclin D1 and inhibits cell proliferation by inducing p53 expression^[1].
Anticancer agent 50 (0.1, 0.5, 2, 10 µM; 72 h) inhibits cell growth by 12% in SH-SY5Y cells^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

563.55

C₃₀H₃₂N₂O₄Se

2487457-15-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ali W, et al. Discovery of phenylselenoether-hydantoin hybrids as ABCB1 efflux pump modulating agents with cytotoxic and antiproliferative actions in resistant T-lymphoma. Eur J Med Chem. 2020 Aug 15;200:112435.